Preliminary
Cellular — Research on cellular-level aging mechanisms
Review / Commentary
PubMed
Scientists designed a drug that kills harmful aging cells in the brain and improved memory in animal tests; early human data are promising but limited.
FOXO4-DRI disrupts the FOXO4-p53 senescence pathway, reducing senescent cell burden and neuroinflammation in preclinical models; translational evidence to human cognitive outcomes remains preliminary and requires larger randomized trials.
This review examines FOXO4-DRI, a designed peptide that kills senescent (aged) cells by disrupting a protein interaction linked to brain aging. Animal studies show it improves memory and reverses some Alzheimer's-like damage, while early human …
Naunyn-Schmiedeberg's archives of pharmacology